Trial of Docetaxel-samarium in Patients With Hormone-refractory Advanced Prostate Cancer

StatusTerminated
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study Identification, Study Status, Sponsor/Collaborators, Oversight, Referencesv4
  2. Trial status: Recruiting to Terminated
    • Site details revised
    v3
  3. Interventions: Docetaxel, samarium (Drug) to docetaxel and samarium (Drug)v2 Show 4 more changesShow less
    • Secondary endpoints revised (3)
    • Site contact updated
    • Eligibility criteria expanded, about 1 word
    • Study title shortened, about 2 words
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective phase II trial of docetaxel-samarium in patients with hormone-refractory advanced prostate cancer who achieve a response or a stabilization to docetaxel-estramustine.
Trial Details
NCT Number NCT00126230
Lead Sponsor Gustave Roussy, Cancer Campus, Grand Paris
Conditions
(from sponsor)		 Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 55 participants
Start Date
Updated on ClinicalTrials.gov